title: Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.
authors.affiliation: a US Oncology Research, Inc. , The Woodlands , TX , USA ;
authors.forename: Robert M
authors.initials: RM
authors.lastname: Rifkin
authors.affiliation: b Indiana University Cancer Center , Indianapolis , IN , USA ;
authors.forename: Rafat
authors.initials: R
authors.lastname: Abonour
authors.affiliation: c Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA ;
authors.forename: Jatin J
authors.initials: JJ
authors.lastname: Shah
authors.affiliation: d Division of Hematology-Oncology , Northwestern University Feinberg School of Medicine , Chicago , IL , USA ;
authors.forename: Jayesh
authors.initials: J
authors.lastname: Mehta
authors.affiliation: e Maryland Oncology Hematology , Columbia , MD , USA ;
authors.forename: Mohit
authors.initials: M
authors.lastname: Narang
authors.affiliation: f Providence Cancer Center Institute, Southfield , MI , USA ;
authors.forename: Howard
authors.initials: H
authors.lastname: Terebelo
authors.affiliation: g Division of Cellular Therapy , Duke University Medical Center , Durham , NC , USA ;
authors.forename: Cristina
authors.initials: C
authors.lastname: Gasparetto
authors.affiliation: h Steeplechase Cancer Center , Somerville , NJ , USA ;
authors.forename: Kathleen
authors.initials: K
authors.lastname: Toomey
authors.affiliation: i Epidemiology and Biostatistics, University of South Carolina , Columbia , SC , USA ;
authors.forename: James W
authors.initials: JW
authors.lastname: Hardin
authors.affiliation: j Celgene Corporation , Summit , NJ , USA ;
authors.forename: Jane Jie
authors.initials: JJ
authors.lastname: Lu
authors.affiliation: j Celgene Corporation , Summit , NJ , USA ;
authors.forename: Laurie
authors.initials: L
authors.lastname: Kenvin
authors.affiliation: j Celgene Corporation , Summit , NJ , USA ;
authors.forename: Shankar
authors.initials: S
authors.lastname: Srinivasan
authors.affiliation: j Celgene Corporation , Summit , NJ , USA ;
authors.forename: Robert
authors.initials: R
authors.lastname: Knight
authors.affiliation: j Celgene Corporation , Summit , NJ , USA ;
authors.forename: Yasir
authors.initials: Y
authors.lastname: Nagarwala
authors.affiliation: k Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute , Los Angeles , CA , USA.
authors.forename: Brian G M
authors.initials: BG
authors.lastname: Durie
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D000077269:Lenalidomide; D008297:Male; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000453:epidemiology* / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000453:epidemiology*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012042:Registries; D018426:SEER Program; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D013792:Thalidomide; D000077269:Lenalidomide